Myotonic dystrophy type 1, also known as Steinert＇s disease, is an autosomal dominant disorder with multisystemic clinical features affecting the skeletal and cardiac muscles, the eyes, and the endocrine system. Thia...Myotonic dystrophy type 1, also known as Steinert＇s disease, is an autosomal dominant disorder with multisystemic clinical features affecting the skeletal and cardiac muscles, the eyes, and the endocrine system. Thiamine （vitamin B1） is a cofactor of fundamental enzymes involved in the energetic cell me- tabolism; recent studies described its role in oxidative stress, protein processing, peroxisomal function, and gene expression. Thiamine deficiency is critical mainly in the central and peripheral nervous system, as well as in the muscular cells. Our aim was to investigate the potential therapeutical effects of long-term treatment with thiamine in myotonic dystrophy type 1 in an observational open-label pilot study. We de- scribed two patients with myotonic dystrophy type 1 treated with intramuscular thiamine 100 mg twice a week for 12 or 11 months. We evaluated the patients using the grading of muscle strength according to Medical Research Council （MRC）, the Muscular Impairment Rating Scale （MIRS）, and the Modified Barthel index. High-dose thiamine treatment was well tolerated and effective in improving the motor symptomatology, particularly the muscle strength evaluated with the MRC scale, and the patients＇ activi- ties of daily living using the Modified Barthel Index. At the end of treatment, the MRC score was 5 in the proximal muscles and 2-4 in the distal muscles （the MRG score before the treatment was 3-4 and 1-3, re- spectively）. The MIRS grade improved by 25% compared to baseline for both patients. In patient #1, the Modified Barthel Index improved by 44%, and in patient #2 by 29%. These findings suggest that clinical outcomes are improved by long-term thiamine treatment.展开更多
目的对一个2A型肢带型肌营养不良(limb-girdle muscular dystrophy type 2A)家系进行CAPN3基因的致病突变分析。方法收集先证者及家系成员的外周血,提取DNA,应用全外显子测序技术对先证者进行致病基因检测,然后用Sanger测序技术对先证...目的对一个2A型肢带型肌营养不良(limb-girdle muscular dystrophy type 2A)家系进行CAPN3基因的致病突变分析。方法收集先证者及家系成员的外周血,提取DNA,应用全外显子测序技术对先证者进行致病基因检测,然后用Sanger测序技术对先证者家系成员进行突变位点的验证。结果全外显子测序发现先证者携带CAPN3基因c.1194-9A>G和c.1437C>T(p.ser479=)的复合杂合突变。Sanger测序验证先证者母亲为CAPN3基因c.1194-9A>G变异携带者。家系中其他患者均存在相同的复合杂合突变,其未发病的姐姐和女儿为CAPN3基因c.1437C>T(p.ser479=)变异携带者,先证者的女婿未检测到上述位点变异。结论CAPN3基因c.1194-9A>G和c.1437C>T(p.ser479=)的复合杂合突变为该家系的致病原因。展开更多
文摘Myotonic dystrophy type 1, also known as Steinert＇s disease, is an autosomal dominant disorder with multisystemic clinical features affecting the skeletal and cardiac muscles, the eyes, and the endocrine system. Thiamine （vitamin B1） is a cofactor of fundamental enzymes involved in the energetic cell me- tabolism; recent studies described its role in oxidative stress, protein processing, peroxisomal function, and gene expression. Thiamine deficiency is critical mainly in the central and peripheral nervous system, as well as in the muscular cells. Our aim was to investigate the potential therapeutical effects of long-term treatment with thiamine in myotonic dystrophy type 1 in an observational open-label pilot study. We de- scribed two patients with myotonic dystrophy type 1 treated with intramuscular thiamine 100 mg twice a week for 12 or 11 months. We evaluated the patients using the grading of muscle strength according to Medical Research Council （MRC）, the Muscular Impairment Rating Scale （MIRS）, and the Modified Barthel index. High-dose thiamine treatment was well tolerated and effective in improving the motor symptomatology, particularly the muscle strength evaluated with the MRC scale, and the patients＇ activi- ties of daily living using the Modified Barthel Index. At the end of treatment, the MRC score was 5 in the proximal muscles and 2-4 in the distal muscles （the MRG score before the treatment was 3-4 and 1-3, re- spectively）. The MIRS grade improved by 25% compared to baseline for both patients. In patient #1, the Modified Barthel Index improved by 44%, and in patient #2 by 29%. These findings suggest that clinical outcomes are improved by long-term thiamine treatment.
文摘目的对一个2A型肢带型肌营养不良(limb-girdle muscular dystrophy type 2A)家系进行CAPN3基因的致病突变分析。方法收集先证者及家系成员的外周血,提取DNA,应用全外显子测序技术对先证者进行致病基因检测,然后用Sanger测序技术对先证者家系成员进行突变位点的验证。结果全外显子测序发现先证者携带CAPN3基因c.1194-9A>G和c.1437C>T(p.ser479=)的复合杂合突变。Sanger测序验证先证者母亲为CAPN3基因c.1194-9A>G变异携带者。家系中其他患者均存在相同的复合杂合突变,其未发病的姐姐和女儿为CAPN3基因c.1437C>T(p.ser479=)变异携带者,先证者的女婿未检测到上述位点变异。结论CAPN3基因c.1194-9A>G和c.1437C>T(p.ser479=)的复合杂合突变为该家系的致病原因。
